The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients

Peer Review reports

Original Submission
28 Mar 2018	Submitted	Original manuscript
28 May 2018	Author responded	Author comments - Marilena Petrera
Resubmission - Version 2
28 May 2018	Submitted	Manuscript version 2
14 Oct 2018	Author responded	Author comments - Marilena Petrera
Resubmission - Version 3
14 Oct 2018	Submitted	Manuscript version 3
Publishing
22 Nov 2018	Editorially accepted
4 Dec 2018	Article published	10.1186/s12885-018-5126-7

Back to article page